The Effect of Anacetrapib on Vascular Function and Arterial Stiffness

Overview

There are currently no studies evaluating the effect of anacetrapib on blood vessel function and stiffness of the arteries. The REVEAL-Vasc trial will assess whether anacetrapib, in addition to atorvastatin (LDL-C lowering drug) treatment, results in greater endothelial-dependent vascular function and aortic stiffness in patients with established cardiovascular disease, compared to adding placebo.

Participants will be asked to provide a blood sample and pulse Wave Velocity/Pulse Wave Analysis and Flow Mediated Dilation will be carried out to assess blood vessel function and stiffness of the arteries. REVEAL-Vasc is an investigator led sub-study of HPS3/TIMI 55: REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease (NCT01252953) which is coordinated by OXFORD CTSU.

No treatment will be received on this sub-study, therefore only participants who have been enrolled in HPS3/TIMI55 REVEAL in which participants received anacetrapib with atorvastatin or placebo will be considered for this trial.

Full Title of Study: “A Cross-sectional REVEAL Sub-study Evaluating the Effect of Anacetrapib on Vascular Function and Arterial Stiffness [An Investigator Led Sub-study of HPS3/TIMI 55: REVEAL]“

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: May 2018

Detailed Description

REVEAL-Vasc is an investigator led sub-study of HPS3/TIMI 55: REVEAL. Participants who previously enrolled on HPS3/TIMI 55: REVEAL and received treatment will be invited to participate in this sub-study. Participants will attend a screening and an assessment visit during which Pulse Wave Velocity/ Pulse Wave Analysis and Flow Mediated Dilation will be carried out to assess blood vessel function and stiffness. A blood sample will also be taken from participant to assess CRP and lipid profile. Since participants will have received treatment on the main trial HPS3/TIMI 55: REVEAL, no treatment will be received on this sub-study.

Interventions

  • Drug: Anacetrapib
    • No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
  • Drug: Statin
    • No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
  • Drug: Placebo
    • No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)

Arms, Groups and Cohorts

  • Anacetrapib
    • Participants who received anacetrapib, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
  • Placebo
    • Participants who received placebo, in addition to statin on the HPS3/TIMI 55: REVEAL trial.

Clinical Trial Outcome Measures

Primary Measures

  • The effect of treatment on flow-mediated dilation (FMD)
    • Time Frame: Visits 0-1 (day 0 up to approximately day 28 depending on scheduling of visits)
    • Measured by FMD as a surrogate measure of endothelial-dependent vasodilation

Secondary Measures

  • The effect of treatment on aortic (carotid-to-femoral) Pulse Wave Velocity (PWV)
    • Time Frame: Visits 0-1 (day 0 up to approximately day 28 depending on scheduling of visits)
    • Measured by PWV as a surrogate measure of aortic stiffness
  • The effect of treatment on central blood pressure
    • Time Frame: Visits 0-1 (day 0 up to approximately day 28 depending on scheduling of visits)
    • As a measure of central haemodynamics
  • The effect of treatment on sublingual glyceryl trinitrate (GTN) response on artery dilation
    • Time Frame: Visits 0-1 (day 0 up to approximately day 28 depending on scheduling of visits)
    • Measured by FMD as a surrogate measure of endothelial-independent vasodilation

Participating in This Clinical Trial

Inclusion Criteria

  • Participants who have been randomised into the HPS3/TIMI 55- REVEAL study (NCT01252953)

Exclusion Criteria

  • Any concomitant condition that, at the discretion of the investigator, may affect the participant's ability to complete the study or study procedures
  • Atrial fibrillation at time of assessment
  • Inability to provide informed consent
  • Inability to refrain from caffeine containing products for 6 hours prior to study visit
  • Inability to refrain from smoking for 2 hours prior to study visit

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Cambridge University Hospitals NHS Foundation Trust
  • Collaborator
    • British Heart Foundation Cambridge Centre of Excellence
  • Provider of Information About this Clinical Study
    • Principal Investigator: Joseph Cheriyan, MD, Consultant Clinical Pharmacologist & Physician/Associate Lecturer – Cambridge University Hospitals NHS Foundation Trust
  • Overall Official(s)
    • Joseph Cheriyan, MBChB, MA, FRCP, Principal Investigator, Cambridge University Hospitals NHS Foundation Trust

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.